Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan

被引：0
|
作者：
C. Arrichiello
L. Aloj
M. Mormile
L. D’Ambrosio
F. Frigeri
C. Caracò
M. Arcamone
F. De Martinis
A. Pinto
S. Lastoria
机构：
[1] Istituto Nazionale per lo Studio e la Cura dei Tumori,Nuclear Medicine Department
[2] Fondazione “G. Pascale”,Hematology
[3] Istituto Nazionale per lo Studio e la Cura dei Tumori,Oncology and Stem Cells Transplantation Unit, Department of Hematology
[4] Fondazione “G. Pascale”,IRCCS
[5] Istituto Nazionale per lo Studio e la Cura dei Tumori,undefined
[6] Fondazione “G. Pascale”,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2012年 / 39卷
关键词：
Radioimmunotherapy; Ibritumomab tiuxetan; Non-Hodgkin’s lymphoma; Dosimetry; Bremsstrahlung imaging;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：956 / 966
页数：10
相关论文
共 50 条
  • [1] Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan
    Arrichiello, C.
    Aloj, L.
    Mormile, M.
    D'Ambrosio, L.
    Frigeri, F.
    Caraco, C.
    Arcamone, M.
    De Martinis, F.
    Pinto, A.
    Lastoria, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (06) : 956 - 966
  • [2] Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan
    Brockmann, H
    Biersack, HJ
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2006, 131 (09) : 438 - 440
  • [3] Accurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan
    Siegel, JA
    Zimmerman, BE
    Kodimer, K
    Dell, MA
    Simon, WE
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (03) : 450 - 454
  • [4] Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin®)
    Bello, P.
    Almoguera, M. I.
    Pajares, M.
    Olivas, C.
    Lapena, L.
    Freire, J. M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2010, 29 (01): : 50 - 52
  • [5] Occupational Dose Measurements For Personnel Performing 90Y-Ibritumomab Tiuxetan Administration
    Law, M.
    Ng, S.
    Liu, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S267 - S268
  • [6] Estimates of Radiation-Absorbed Dose to Kidneys in Patients Treated with 90Y-Ibritumomab Tiuxetan
    Baechler, Sebastien
    Hobbs, Robert F.
    Prideaux, Andrew R.
    Recordon, Melanie
    Bischof-Delaloye, Angelika
    Sgouros, George
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (05) : 633 - 639
  • [7] Detection of Y-90 Extravasation by Bremsstrahlung Imaging for Patients Undergoing Y-90-Ibritumomab Tiuxetan Therapy
    Rhymer, Stephanie M.
    Parker, J. Anthony
    Palmer, Matthew R.
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2010, 38 (04) : 195 - 198
  • [8] A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry
    F. Morschhauser
    B. Dekyndt
    C. Baillet
    C. Barthélémy
    E. Malek
    J. Fulcrand
    P. Bigot
    D. Huglo
    B. Décaudin
    N. Simon
    P. Odou
    Scientific Reports, 8
  • [9] A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry
    Morschhauser, F.
    Dekyndt, B.
    Baillet, C.
    Barthelemy, C.
    Malek, E.
    Fulcrand, J.
    Bigot, P.
    Huglo, D.
    Decaudin, B.
    Simon, N.
    Odou, P.
    SCIENTIFIC REPORTS, 2018, 8
  • [10] Update on the rational use of 90Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
    Lehnert, Martina
    Ludwig, Heinz
    Zojer, Niklas
    ONCOTARGETS AND THERAPY, 2009, 2 : 199 - 208
12345